StockpollyBeta
Get App
Popularity #29
MRNA · NASDAQ · Biotechnology

Moderna (MRNA)

Commercializes mRNA respiratory vaccines while developing oncology and rare-disease therapies.

$171.50
vs last close−1.44 (−0.83%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue1,8312,8131672211,8559561071421,016678389145
Cost of revenue2,24192996115514739901191,00845295593
Gross profit−4101,884711061,34121717238226−56652
1,6021,8781,3371,4691,4111,4631,0679302681,083822867
Research & development1,1601,4061,0271,2211,1371,122856700801775649651
442470274268281351212230268308173216
Selling & marketing02040000000000
General & administrative02660000000000
Other expenses0236−20−7−10−10−801000
Operating income−2,0126−1,266−1,363−70−1,246−1,050−907−260−857−1,388−815
5464101849162868973585448
Interest income10510312011110391908173707267
Interest expense10666661108170
Other non-operating income−64−70−107−90−97−68−87−90−73−58−71−48
Income before tax−1,95870−1,165−1,27921−1,184−964−818−187−799−1,334−767
Income tax expense1,672−1471008−64771327915
Net income from continuing operations−3,630217−1,175−1,27913−1,120−971−825−200−826−1,343−782
Net income−3,630217−1,175−1,27913−1,120−971−825−200−826−1,343−782
EPS, basic−$9.53$0.57−$3.08−$3.33$0.03−$2.91−$2.52−$2.13−$0.51−$2.11−$3.40−$1.96
EPS, diluted−$9.53$0.55−$3.08−$3.33$0.03−$2.91−$2.52−$2.13−$0.51−$2.11−$3.40−$1.96
Weighted average shares, basic381381382384385385386388390392395396
Weighted average shares, diluted381395382384399385386388390392395396
EBITDA−1,699278−1,123−1,23279−1,118−924−760−135−732−1,258−704
Depreciation & amortization24920236415260395752675963
EBIT−1,94876−1,159−1,27327−1,178−963−817−187−799−1,317−767